En español

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)

This study will assess the comparative effectiveness of extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking heroin- and/or prescription opioid-dependent participants.  The primary goal of the study is to estimate the difference, if one exists, between XR-NTX and BUP-NX in the distribution of the time to relapse during the 6-month trial.

CTN Protocol ID: 
Enrollment Status: 
ClinicalTrials.gov ID: 
Principal Investigator(s)
John Rotrosen, M.D.
NYU School of Medicine
Department of Psychiatry
One Park Avenue, 8th Floor
New York, NY 10016

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.